EWTX News and Press, Edgewise Therapeutics Inc. From 05/18/22

The following slide deck was published by Edgewise Therapeutics, Inc. in conjunction with this event. For further details see: Edgewise Therapeutics (EWTX) Investor Presentation - Slideshow

Edgewise Therapeutics press release (NASDAQ:EWTX): Q1 GAAP EPS of -$0.30 misses by $0.02. Cash, cash equivalents and marketable securities of $265.8 million as of March 31, 2022 For further details see: Edgewise Therapeutics GAAP EPS of -$0.30 misses by $0.02

– Completed enrollment of the ARCH open label study of EDG-5506 in Becker muscular dystrophy (BMD) – – Enrollment initiated in Edgewise-funded Natural History Trial of BMD – – Phase 2 trials in BMD and Duchenne muscular dystrophy (DMD...

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today that members of its senior management team will participate in fireside...

- Trial to inform the disease progression of individuals with BMD - Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, today an...

Halvorsen's 13F portfolio value decreased from $36.04B to $34.49B this quarter. The number of positions increased from 96 to 107. Viking Global added Twilio, Workday, and Aon plc while dropping Fidelity National Information Services and Snowflake. The top three positions are Ginkg...

– Podium presentations on March 15 and 16, 2022 – – Company to host a conference symposium to discuss its new approach to protecting dystrophic muscle featuring a key opinion leader – Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical...

Edgewise Therapeutics press release (NASDAQ:EWTX): Q4 GAAP EPS of -$0.26 beats by $0.02. “2021 was a tremendous year for Edgewise starting with our successful initial public offering that provided financial stability to grow our talented team and advance our pipeline of product candida...

– Announced positive topline results from the EDG-5506 Phase 1b clinical trial in adults with Becker muscular dystrophy (BMD) – – Phase 2 trials in BMD and Duchenne muscular dystrophy (DMD) planned to start in 2022 – – Cash, cash equi...

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today that members of its senior management team will participate in a firesi...